Leadership Changes at Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a leader in the biotechnology sector focused on developing tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has announced the appointment of Corleen Roche as Chief Financial Officer (CFO). This strategic decision underscores Iovance's commitment to enhance its leadership as it prepares for its first commercial launch.
Bringing Expertise to the Team
In welcoming Corleen Roche, Frederick G. Vogt, Ph.D., J.D., who serves as Interim Chief Executive Officer, stated, "Corleen's extensive expertise in financial leadership roles across high-stakes environments will be crucial as we navigate our path to revenue growth and operational efficiency." Roche's background in the biotech and life sciences industry spans over 30 years, showcasing a history of impactful leadership in public companies.
A Robust Career in Finance
Before joining Iovance, Ms. Roche served as CFO at CG Oncology, a company specializing in biopharmaceuticals. She has also held key financial positions at Immunome, Biogen, CSL Behring, and within the Sandoz, Wyeth, and Pfizer networks. Her proven track record includes launching critical products like ZARXIO, recognized as the first U.S. approved biosimilar, and the innovative GLATOPA for multiple sclerosis.
Commitment to Innovation and Growth
Roche expressed her eagerness to join Iovance, stating, "I look forward to focusing our pipeline investments on high-value opportunities while maintaining a dedicated approach to our mission to affect patients' lives positively. We aim to build a profitable biotechnology company that prioritizes patient welfare."
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. aspires to lead in the development of novel TIL therapies. They aim to revolutionize cancer treatment by leveraging the human immune system's natural ability to target and eliminate cancer cells. Their TIL platform is noted for its promising results across various solid tumors, and the FDA has approved Amtagvi as the first T-cell therapy for specific solid tumor indications.
Future Directions and Innovations
The company's ongoing work emphasizes continuous improvement and innovation in cellular therapy technologies, including exploring gene-edited therapies that could significantly enhance patients' quality of life.
Contact Information
Investors:
Email: IR@iovance.com
Phone: 650-260-7120 ext. 150
Media:
Email: PR@iovance.com
Phone: 650-260-7120 ext. 150
Frequently Asked Questions
1. Who is the new CFO of Iovance Biotherapeutics?
Corleen Roche has been appointed as the new Chief Financial Officer of Iovance Biotherapeutics.
2. What is Iovance Biotherapeutics known for?
Iovance Biotherapeutics is recognized for its innovative tumor infiltrating lymphocyte (TIL) therapies aimed at treating cancer.
3. What prior experience does Corleen Roche bring to her role?
Corleen Roche has over 30 years of experience in financial leadership roles within the biotech sector, having served as CFO at several prominent companies.
4. What innovations is Iovance pursuing?
Iovance is focusing on developing cutting-edge therapies including gene-edited cell therapies that aim to enhance cancer treatment.
5. How can investors contact Iovance?
Investors can reach out to Iovance at IR@iovance.com or call 650-260-7120 ext. 150 for inquiries.
